Study of IV tocilizumab for GCA that led to FDA approval of intravenous TCZ this year (2/2022) -one of Dr. C Langford's pick for #YearinReview @rheumnow #ACR22 https://t.co/luxDDluddM

• Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia R…

Is it the medication or behaviour that increases mortality? #SLICC grp showed in #SLE severe non-adherence to #HCQ in Yr 1 of #lupus = 3 poor outcomes -more 1 flares, 2 damage, 3 5yr-death. Surrogate of other poor health behaviours and/or HCQ? abst#0343 #ACR22 #ACRBest @RheumNow https://t.co/tTRdyti0sf

Ab0343. #ACR22 Severe non-adherence of HCQ associated with FLARES, DAMAGE and DEATH 7.3% had "severe non-adherence" by HCQ levels Hazard ratio of flare 3.3, damage 4.26, and death 5.4 Not surprising, but very useful for pt discussion Checking HCQ levels are helpful! @Rheumnow https://t.co/S7P9oTPRGJ

Ab0344 #ACR22 CKD2+ a/w incr HCQ levels by 149 ng/mL vs CKD1 400 mg/d dose: incr HCQ levels by 448 ng/mL vs 200 Incr body wt by 15 kg -> decr HCQ levels by 82 ng/mL Social determinants didn't effect data >750ng/mL and >1000 predicted of 75% decr flare risk @Rheumnow #ACRBest https://t.co/p21rqnO4ym

Dr. C Langford on #YearinReview: ORAL Surveillance noted NNH=16 in pts w/ASCVD compared to NNH 223 in pts w/o ASCVD. This led to FDA warning on all JAKi; how does not this apply to the new JAKi's? Discussion needed with patients when starting this class of drug #ACR22 @rheumnow https://t.co/XtJVap6yjh

Year in Review #acr22 Oral Surveillance: With ASCVD number needed to harm 16, only 223 without ASCVD Focus on risk stratification ⁦@RheumNow⁩ https://t.co/tJyha1WKfR

ORAL surveillance the big talking factor over the last year. NNH of 16(!) for CV event (over 5 yrs) in those with history of atherosclerotic CV disease. @RheumNow #ACR22 #yearinreview #ACRBest

Great start to year in review. Beginning with JAKinibs in the much talked about ORAL Surveillance study. Good Review of the mechanisms of action for JAKinibs @RheumNow #ACR22 https://t.co/IF0t4uSefj

Abstr #0078 Ogdie et al found that - Pts seen by rheumatologists more likely receive bDMARDs or csDMARDs - Opiates & non-Opiate pain medications were more commonly prescribed to pts seen by PCPs alone @RheumNow #ACR22 https://t.co/uDcOc0Nn3Y https://t.co/FeAq21fiVs

• Treatment of Ankylosing Spondylitis by Primary Care Physicians and Rheumatologi…